Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more
Mayne Pharma Group Limited (MAYNF) - Total Assets
Latest total assets as of June 2025: $1.01 Billion USD
Based on the latest financial reports, Mayne Pharma Group Limited (MAYNF) holds total assets worth $1.01 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mayne Pharma Group Limited - Total Assets Trend (2007–2025)
This chart illustrates how Mayne Pharma Group Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Mayne Pharma Group Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Mayne Pharma Group Limited's total assets of $1.01 Billion consist of 34.8% current assets and 65.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.9% |
| Accounts Receivable | $164.62 Million | 16.2% |
| Inventory | $50.56 Million | 5.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $542.11 Million | 53.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Mayne Pharma Group Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mayne Pharma Group Limited's current assets represent 34.8% of total assets in 2025, a decrease from 99.6% in 2007.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, down from 98.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 53.4% of total assets.
Mayne Pharma Group Limited Competitors by Total Assets
Key competitors of Mayne Pharma Group Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
|
China | CN¥67.71 Billion |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
China | CN¥3.56 Billion |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
China | CN¥15.33 Billion |
|
Hanmi Science
KO:008930
|
Korea | ₩1.45 Trillion |
|
BCM Alliance Bhd
KLSE:0187
|
Malaysia | RM147.86 Million |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥7.59 Billion |
|
Excelsior Medical Co Ltd
TW:4104
|
Taiwan | NT$18.80 Billion |
|
CHC Healthcare Group
TW:4164
|
Taiwan | NT$14.83 Billion |
Mayne Pharma Group Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Mayne Pharma Group Limited generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Mayne Pharma Group Limited is currently not profitable relative to its asset base.
Mayne Pharma Group Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.47 | 2.24 |
| Quick Ratio | 1.16 | 1.23 | 1.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $91.78 Million | $ 146.66 Million | $ 271.69 Million |
Mayne Pharma Group Limited - Advanced Valuation Insights
This section examines the relationship between Mayne Pharma Group Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -11.2% |
| Total Assets | $1.01 Billion |
| Market Capitalization | $183.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mayne Pharma Group Limited's assets below their book value (0.18 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mayne Pharma Group Limited's assets decreased by 11.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mayne Pharma Group Limited (2007–2025)
The table below shows the annual total assets of Mayne Pharma Group Limited from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $1.01 Billion | -11.25% |
| 2024-06-30 | $1.14 Billion | -8.41% |
| 2023-06-30 | $1.25 Billion | -3.09% |
| 2022-06-30 | $1.29 Billion | -11.98% |
| 2021-06-30 | $1.46 Billion | -19.83% |
| 2020-06-30 | $1.83 Billion | +11.54% |
| 2019-06-30 | $1.64 Billion | -10.61% |
| 2018-06-30 | $1.83 Billion | -4.41% |
| 2017-06-30 | $1.91 Billion | +22.96% |
| 2016-06-30 | $1.56 Billion | +194.43% |
| 2015-06-30 | $528.95 Million | +98.99% |
| 2014-06-30 | $265.82 Million | +13.89% |
| 2013-06-30 | $233.39 Million | +332.74% |
| 2012-06-30 | $53.93 Million | +0.48% |
| 2011-06-30 | $53.68 Million | -24.56% |
| 2010-06-30 | $71.15 Million | +785.41% |
| 2009-06-30 | $8.04 Million | -31.28% |
| 2008-06-30 | $11.69 Million | -24.61% |
| 2007-06-30 | $15.51 Million | -- |